# Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose

> **NCT01978028** · PHASE4 · TERMINATED · sponsor: **University of Zurich** · enrollment: 20 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** ferric carboxymaltose
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01978028
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Slow recruitment
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978028, "Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01978028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*